2025
2070-LB: Modeling to Assess the Impact of Liquid, Stable Glucagon for Mini-dosing in Pediatrics—A Simulated Pharmacokinetic and Pharmacodynamic Study
FITCH R, MOULD D, SHERR J, LAFFEL L, NALLY L, FERGUSON N. 2070-LB: Modeling to Assess the Impact of Liquid, Stable Glucagon for Mini-dosing in Pediatrics—A Simulated Pharmacokinetic and Pharmacodynamic Study. Diabetes 2025, 74 DOI: 10.2337/db25-2070-lb.Peer-Reviewed Original ResearchMini-dose glucagonBaseline glucose levelsGlucagon doseGlucose levelsVisual predictive checkY/O groupMini-dosePediatric groupPediatric populationPharmacodynamic studiesClinical studiesPediatric studiesGlucose excursionsDose responseDoseAged 2Glucose responseAge-weight relationshipGlucagonImpending hypoglycemiaPredictive checksBaselineGlucoseMicro-dosingGroupOutcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16‐Negative Oropharyngeal Cancers
Zakeri K, Wren S, Shang T, Yu Y, Chen L, Shamseddine A, Safavi A, Kang J, Tsai C, Sherman E, Wong R, McBride S, Gelblum D, Riaz N, Lee N. Outcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16‐Negative Oropharyngeal Cancers. Head & Neck 2025 PMID: 40515499, DOI: 10.1002/hed.28217.Peer-Reviewed Original ResearchP16-negative oropharyngeal cancerNodal recurrenceLocoregional recurrenceP16-negativeDistant recurrenceOropharyngeal cancerHead and neck cancer patientsRadiation doseDecrease treatment toxicityNeck cancer patientsPrimary outcome measureConcurrent chemoradiationRadiotherapy doseMedian followConsecutive patientsTreatment toxicityImprove quality of lifeConsecutive cohortCancer patientsRecurrenceQuality of lifeHypopharyngealDosePatientsOutcome measuresOne-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma.
Dholaria H, Tsetlina V, Simpson S, Gillies E, Eswaran N, Rodriguez-Galindo C, Schultz K, Chen K, Wu C, Krasin M, Roemer T, Christiansen H, Piao J, Laetsch T, Pashankar F, Kontny U, Gartrell R. One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma. Clinical Cancer Research 2025, of1-of9. PMID: 40445588, DOI: 10.1158/1078-0432.ccr-24-3546.Peer-Reviewed Original ResearchGerman Society of Pediatric Oncology and HematologyChildren's Oncology GroupNasopharyngeal carcinomaClinical trialsAnti-PD-1 therapyRadiation doseDecreased radiation dosePediatric clinical trialsSevere side effectsConcomitant chemotherapyAdjuvant immunotherapyInduction chemotherapyOncology GroupRelated toxicityTreated patientsExcellent survivalSide effectsChemotherapyLate effectsLong-term effectsImmunotherapyCarcinomaClinical priorityDoseResponse-adaptiveOpioid Dose Variation in Cardiac Surgery: A Multicenter Study of Practice
Fisher C, Janda A, Zhao X, Deng Y, Bardia A, Yanez N, Burns M, Aziz M, Treggiari M, Mathis M, Lin H, Schonberger R. Opioid Dose Variation in Cardiac Surgery: A Multicenter Study of Practice. Anesthesia & Analgesia 2025, 140: 1016-1027. PMID: 39167548, PMCID: PMC11842693, DOI: 10.1213/ane.0000000000007128.Peer-Reviewed Original ResearchCardiac surgeryOpioid doseDose variationIntraoperative opioid administrationIntraoperative opioid doseHigh-dose opioidsAdult cardiac surgerySurgical differencesOpioid-freeOpioid administrationOpioid useMultimodal analgesiaAnalgesic techniquesCardiopulmonary bypassMulticenter studyFentanyl equivalentsSufentanil infusionSurgical patientsOpioidSurgeryAnesthetic techniqueCardiac casesAttending anesthesiologistPatientsDoseMethadone for Opioid Use Disorder in the Fentanyl Era: Navigating Challenges and Evolving Strategies- a Narrative Review
Osagie E, Horton J, Lawrence D, Hermes G, Garcia-Vassallo G. Methadone for Opioid Use Disorder in the Fentanyl Era: Navigating Challenges and Evolving Strategies- a Narrative Review. Current Addiction Reports 2025, 12: 44. DOI: 10.1007/s40429-025-00655-6.Peer-Reviewed Original ResearchOpioid use disorderDosing flexibilityEffective treatmentMethadone treatmentCornerstone of treatmentOpioid use disorder treatmentMethadone initiationMethadone doseDosing daysDosing considerationsDose selectionTreatment outcomesUse disorderWithdrawal managementPresence of fentanylOpioidRate of titrationDoseMethadoneFentanylSummaryThis reviewSynthetic opioidsDrug overdose deathsInitial careClinical decisionsNatriuretic response prediction equation for use with oral diuretics in heart failure
Ivey-Miranda J, Rao V, Cox Z, Moreno-Villagomez J, Mastache D, Collins S, Testani J. Natriuretic response prediction equation for use with oral diuretics in heart failure. European Heart Journal 2025, 46: 2410-2418. PMID: 40272149, PMCID: PMC12208776, DOI: 10.1093/eurheartj/ehaf268.Peer-Reviewed Original ResearchConceptsMechanisms of diuretic resistanceArea under the curvePoor diuretic responseDiuretic responseHeart failureDiuretic doseOral diureticsNatriuretic responseHF patient cohortsLoop diuretic doseOral loop diureticsUrine samplesTimed urine collectionsOral loopDiuretic resistanceLoop diureticsDiuretic administrationUrine volumePatient cohortUrine collectionStudy visitsDiureticsPatientsUrineDoseFeasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Scott S, Roberts D, Gupta V, Joseph N, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract. Clinical Lymphoma Myeloma & Leukemia 2025 PMID: 40345961, DOI: 10.1016/j.clml.2025.04.002.Peer-Reviewed Original ResearchStep-up dosingRelapsed/refractory multiple myelomaTarget doseInstitutional protocolRelapsed/refractory multiple myeloma patientsBispecific antibodiesTreatment of patientsProtocol eligibilityMultiple myelomaT cellsAccelerated approvalToxicity managementLower hospitalization ratesDay 1Low incidenceFDA labelingPatientsCare centerPatient's diseaseNeurological changesHospitalization ratesDoseOral abstractsTocilizumabHospitalMoving Beyond Desensitization to Tolerance in Food Allergy
Flom J, Shreffler W, Perrett K. Moving Beyond Desensitization to Tolerance in Food Allergy. The Journal Of Allergy And Clinical Immunology In Practice 2025, 13: 741-744. PMID: 40010566, DOI: 10.1016/j.jaip.2025.02.014.Peer-Reviewed Original ResearchManagement of IgE-mediated food allergyFood allergyIgE-mediated food allergyStages of clinical developmentSide effect profileMode of deliveryGoal of therapeuticsSustained unresponsivenessDosing regimensDose protocolProactive therapyAllergen-specificClinical developmentActive therapyPatient populationSide effectsTherapyPassive therapyPatient-specificDesensitizationClinical contextPatientsDoseAllergyDegree of protectionAssessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study
Shoukat A, Wells C, Shin T, Potter-Schwartz L, Galvani A, Moghadas S. Assessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study. The Lancet Regional Health - Americas 2025, 44: 101033. PMID: 40046840, PMCID: PMC11880592, DOI: 10.1016/j.lana.2025.101033.Peer-Reviewed Original ResearchInvasive meningococcal diseaseInvasive meningococcal disease casesVaccination scheduleVaccine uptakeAlternative schedulesMenACWY vaccination programCase fatality rateHigh-risk adolescentsVaccine introductionBooster doseIMD casesSerogroup CCompare outcomesMenACWY vaccineAsymptomatic infectionImmunization PracticesMeningococcal diseaseVaccine effectivenessIMD incidenceDoseSerogroups AVaccineStudy periodVaccination programIncrease vaccine uptakeComputational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, Dutta J, El-Fakhri G, McMeekin H, Pandit-Taskar N, Schwartz J, Shi K, Strigari L, Zaidi H, Saboury B, Rahmim A. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories. Journal Of Nuclear Medicine 2025, 66: 509-515. PMID: 39947910, PMCID: PMC11960611, DOI: 10.2967/jnumed.124.267927.Peer-Reviewed Original ResearchRadiopharmaceutical therapyImage-based dosimetryPrediction of doseInternal dosimetryPersonalized treatment plansMetastatic diseaseDosimetryNuclear oncologyClinical outcomesNuclear medicineClinical endpointsTreatment planningOncology communityDose responseEtiological mechanismsTargeted deliveryRadiobiologyRadiotherapyMalignancyRadiationLong-termTherapyPharmacotherapyDoseRadiopharmacokineticsEfficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered
Ogbuagu O, Avihingsanon A, Segal-Maurer S, Wang H, Jogiraju V, Singh R, Rhee M, Dvory-Sobol H, Sklar P, Molina J. Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered. AIDS 2025, 39: 639-648. PMID: 39912752, PMCID: PMC11970582, DOI: 10.1097/qad.0000000000004142.Peer-Reviewed Original ResearchTreatment-emergent AEClinical trialsVirologic suppressionRates of virologic suppressionPlasma concentrationsAdequate plasma concentrationsHIV-1 treatmentConfidence intervalsLens doseLens treatmentMedian durationLenacapavirSC doseHIV-1PharmacokineticsPosthoc analysisDoseWeeksEfficacyTrialsAnalysis of participantsTreatmentInjectionAntiretroviralsSafetySelinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design
Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C. Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design. Future Oncology 2025, 21: 807-813. PMID: 39911057, PMCID: PMC11916360, DOI: 10.1080/14796694.2025.2461393.Peer-Reviewed Original ResearchConceptsJAK inhibitorsNo dose limiting toxicitiesDose-limiting toxicityAbsolute mean changeSpleen volume reductionPlacebo-controlled studyBaseline to weekTreatment of patientsDose expansionDose escalationLimiting toxicitiesDouble-blindPrimary endpointPhase 3 study designXPO1 inhibitorsMean changeRuxolitinibPatientsSelinexorVolume reductionDosePhase 3InhibitorsJAKMyelofibrosisT75 Is Once Daily Enough? Assessing the Impact of Timing of Methadone Dose on Pain Sensitivity via Quantitative Sensory Testing in Persons With Opioid Use Disorder
Ra J, Meyerovich J, Pittman B, De Aquino J, De Aquino J. T75 Is Once Daily Enough? Assessing the Impact of Timing of Methadone Dose on Pain Sensitivity via Quantitative Sensory Testing in Persons With Opioid Use Disorder. Drug And Alcohol Dependence 2025, 267: 111843. DOI: 10.1016/j.drugalcdep.2024.111843.Peer-Reviewed Original ResearchRegional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
Kopp S, Vandermeulen E, McBane R, Perlas A, Leffert L, Horlocker T. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition). Regional Anesthesia & Pain Medicine 2025, rapm-2024-105766. PMID: 39880411, DOI: 10.1136/rapm-2024-105766.Peer-Reviewed Original ResearchAmerican Society of Regional AnesthesiaDeep venous thrombosisEvidence-based guidelinesRegional anesthesiaThrombolytic therapyComplications associated with regional anesthesiaRecurrent deep venous thrombosisAmerican SocietyRandomized controlled trialsAnticoagulant doseNeural blockadeVenous thrombosisCase seriesCatastrophic complicationPatient characteristicsClinical trialsHigh dosesPatientsPublished guidelinesControlled trialsPainAnesthesiaPatient safetyTherapyDose
2024
Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support
Gottesman S, Xiao K, Nguyen H, Hernandez E, Saweris E, Jagannathan P, Jafri F, Davis J, Tong K, Tang Z, Gaidos J, Feagins L. Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support. Clinical And Translational Gastroenterology 2024, 16: e00808. PMID: 39718220, PMCID: PMC11932631, DOI: 10.14309/ctg.0000000000000808.Peer-Reviewed Original ResearchConceptsAdvanced therapiesRisk factorsMulticenter studyMulticenter study of patientsInflammatory bowel disease therapyStudy of patientsAdult inflammatory bowel diseasePatient-related factorsIntravenous drug deliverySmall molecule therapiesLogistic regression analysisInflammatory bowel diseaseBaseline demographicsDisease activityIntravenous infusionMolecule therapiesDisease characteristicsGastroenterology practiceTherapyBowel diseaseInsurance denialPatientsDoseIntravenous inductionCare teamClinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections
Shah S, Adams K, Clarke L, Ludwig J, McManus D, Nguyen M, Topal J, Shields R. Clinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections. International Journal Of Antimicrobial Agents 2024, 65: 107403. PMID: 39667533, DOI: 10.1016/j.ijantimicag.2024.107403.Peer-Reviewed Original ResearchClinical failureDosing strategiesClinical outcomesIncreased risk of clinical failureRetrospective chart review of adult patientsChart review of adult patientsReview of adult patientsRate of clinical failureClinical outcomes of patientsRisk of clinical failureAssociated with worse outcomesOutcomes of patientsRetrospective chart reviewBloodstream infectionsMetronidazole doseAdult patientsWorse outcomesIncreased riskMetronidazolePatientsInclusion criteriaBacteroides sppBacteremiaDoseMortality156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis
Kieseier B, Montalban X, Williams M, Airas L, Saini S, Hide M, Sussman G, Nakahara J, Bermel R, Dörner T, Loop B, DeLasHeras V, Willi R, Haemmerle S, Zharkov A, Barbier N, Azmon A, Siegel R, Cenni B, Haddad I, Wiendl H, Maurer M, Giménez-Arnau A, Chitnis T. 156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis. Multiple Sclerosis And Related Disorders 2024, 92: 106117. DOI: 10.1016/j.msard.2024.106117.Peer-Reviewed Original ResearchAdverse eventsSafety profileOral Bruton's tyrosine kinase inhibitorTreatment of relapsing multiple sclerosisBruton tyrosine kinase inhibitorSkin/subcutaneous tissue disordersUpper respiratory tract infectionMultiple sclerosisTyrosine kinase inhibitorsPhase 3 trialRespiratory tract infectionsGrouped adverse eventsIntegrated safety analysisNervous system disordersTreatment discontinuationTract infectionsRemibrutinibTissue disordersKinase inhibitorsSystem disordersOff-target effectsGastrointestinal disordersDoseInfectionPooled dataA Seamless Phase 2A‐Phase 2B Multi‐Center Trial to Test the Benefits of Benfotiamine on the Progression of Alzheimer’s Disease‐Benfoteam: Design and Methods
Luchsinger J, Feldman H, Messer K, Edland S, Leger G, Jacobs D, Salmon D, Revta C, Lupo J, Durant J, Gibson G. A Seamless Phase 2A‐Phase 2B Multi‐Center Trial to Test the Benefits of Benfotiamine on the Progression of Alzheimer’s Disease‐Benfoteam: Design and Methods. Alzheimer's & Dementia 2024, 20: e091963. PMCID: PMC11714007, DOI: 10.1002/alz.091963.Peer-Reviewed Original ResearchPhase 2bDosing decisionsPerson-months of exposureLonger-term safetyWeeks of treatmentCo-primary endpointsClinically significant benefitBiomarker test resultsMulti-center trialTolerated doseDouble-blindEvaluate safetySmall molecule treatmentBlood levelsActive treatmentPhase 2aThiamine deficiencyPerson-monthsDoseCohen's d effect sizesPharmacological effectsTherapeutic directionsBenfotiamineGlucose metabolismMg/dayVitamin D for very preterm infants—determining the how, when, and why
Taylor S. Vitamin D for very preterm infants—determining the how, when, and why. Pediatric Research 2024, 1-2. PMID: 39496874, DOI: 10.1038/s41390-024-03685-4.Peer-Reviewed Original ResearchEffectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, Ghamande S, Peltan I, Brown S, Ginde A, Steinwand A, Mohr N, Gibbs K, Hager D, Ali H, Frosch A, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Mosier J, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Rhoads J, Swan S, Johnson C, Lewis N, Ellington S, Dawood F, McMorrow M, Self W, Network F. Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza And Other Respiratory Viruses 2024, 18: e70027. PMID: 39496339, PMCID: PMC11534416, DOI: 10.1111/irv.70027.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationIn-hospital outcomesVaccine effectivenessMonovalent dosesAbsolute VETest-negative case-control designInvasive mechanical ventilationCOVID-19 vaccineMultivariate logistic regressionSevere COVID-19Case patientsCase-control designControl patientsMechanical ventilationUnvaccinated patientsPatientsMonovalent vaccineCOVID-19-like illnessDoseCOVID-19 vaccine effectivenessBivalent vaccineLogistic regressionAdmission dateVaccineHospital
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply